Last reviewed · How we verify

Seretide Accuhaler® 500/50 µg/actuation — Competitive Intelligence Brief

Seretide Accuhaler® 500/50 µg/actuation (Seretide Accuhaler® 500/50 µg/actuation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA). Area: Respiratory.

phase 3 Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) Beta-2 adrenergic receptor; glucocorticoid receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Seretide Accuhaler® 500/50 µg/actuation (Seretide Accuhaler® 500/50 µg/actuation) — Chiesi Farmaceutici S.p.A.. Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Seretide Accuhaler® 500/50 µg/actuation TARGET Seretide Accuhaler® 500/50 µg/actuation Chiesi Farmaceutici S.p.A. phase 3 Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/fluticasone Diskus Salmeterol/fluticasone Diskus AstraZeneca marketed Long-acting beta-2 agonist/inhaled corticosteroid combination Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/Fluticasone Capsair® Salmeterol/Fluticasone Capsair® Neutec Ar-Ge San ve Tic A.Ş marketed Long-acting beta-2 agonist/inhaled corticosteroid combination (LABA/ICS) Beta-2 adrenergic receptor; glucocorticoid receptor
Seretide 500 Accuhaler Seretide 500 Accuhaler University of Southampton marketed Long-acting beta-2 agonist / inhaled corticosteroid combination (LABA/ICS) Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/ fluticasone propionate Salmeterol/ fluticasone propionate GlaxoSmithKline marketed Long-acting beta-2 agonist / inhaled corticosteroid combination Beta-2 adrenergic receptor; glucocorticoid receptor
Extra fine Formoterol/Beclomethasone Extra fine Formoterol/Beclomethasone National Institute of Respiratory Diseases, Mexico marketed Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) Beta-2 adrenergic receptor; glucocorticoid receptor
Formoterol/Fluticasone Formoterol/Fluticasone Eurofarma Laboratorios S.A. phase 3 Long-acting beta-2 agonist / Inhaled corticosteroid combination Beta-2 adrenergic receptor; Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) class)

  1. Chiesi Farmaceutici S.p.A. · 1 drug in this class
  2. National Institute of Respiratory Diseases, Mexico · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Seretide Accuhaler® 500/50 µg/actuation — Competitive Intelligence Brief. https://druglandscape.com/ci/seretide-accuhaler-500-50-g-actuation. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: